NTLA
Price
$12.07
Change
+$0.45 (+3.87%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.29B
61 days until earnings call
PRME
Price
$3.71
Change
+$0.31 (+9.12%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
663.18M
56 days until earnings call
Interact to see
Advertisement

NTLA vs PRME

Header iconNTLA vs PRME Comparison
Open Charts NTLA vs PRMEBanner chart's image
Intellia Therapeutics
Price$12.07
Change+$0.45 (+3.87%)
Volume$120.46K
Capitalization1.29B
Prime Medicine
Price$3.71
Change+$0.31 (+9.12%)
Volume$26.5K
Capitalization663.18M
NTLA vs PRME Comparison Chart in %
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. PRME commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (NTLA: $12.06 vs. PRME: $3.40)
Brand notoriety: NTLA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 112% vs. PRME: 29%
Market capitalization -- NTLA: $1.29B vs. PRME: $663.18M
NTLA [@Biotechnology] is valued at $1.29B. PRME’s [@Biotechnology] market capitalization is $663.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than PRME.

Price Growth

NTLA (@Biotechnology) experienced а +6.21% price change this week, while PRME (@Biotechnology) price change was -1.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

PRME is expected to report earnings on Oct 31, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.3B) has a higher market cap than PRME($663M). PRME YTD gains are higher at: 16.438 vs. NTLA (3.431). PRME has higher annual earnings (EBITDA): -197.38M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. PRME (102M). NTLA has less debt than PRME: NTLA (103M) vs PRME (120M). NTLA has higher revenues than PRME: NTLA (52.9M) vs PRME (4.96M).
NTLAPRMENTLA / PRME
Capitalization1.3B663M195%
EBITDA-501.87M-197.38M254%
Gain YTD3.43116.43821%
P/E RatioN/AN/A-
Revenue52.9M4.96M1,066%
Total Cash460M102M451%
Total Debt103M120M86%
FUNDAMENTALS RATINGS
NTLA vs PRME: Fundamental Ratings
NTLA
PRME
OUTLOOK RATING
1..100
752
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
4939
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7527

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for PRME (64) in the null industry. This means that NTLA’s stock grew somewhat faster than PRME’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (39) in the null industry is in the same range as NTLA (49) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 16 days ago
87%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UMBHX30.57N/A
N/A
Carillon Chartwell Small Cap I
JNMCX16.34N/A
N/A
Janus Henderson Mid Cap Value D
TEQSX12.88N/A
N/A
Nuveen Emerging Markets Eq Idx Retire
BCSAX9.43N/A
N/A
BlackRock Commodity Strategies Inv A
HILFX35.58N/A
N/A
Hennessy Large Cap Financial Instl

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+1.80%
CRSP - PRME
58%
Loosely correlated
-0.45%
RXRX - PRME
54%
Loosely correlated
-2.38%
BEAM - PRME
54%
Loosely correlated
-1.17%
CRBU - PRME
48%
Loosely correlated
-2.12%
NTLA - PRME
46%
Loosely correlated
-0.77%
More